A Phase 1 interventional study of Nicotinamide riboside (NR) in Smooth Muscle Dysfunction Syndrome (SMDS), sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by The University of Texas Health Science Center, Houston · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Stroke by The University of Texas Health Science Center, Houston — 6 open to participants now, 9 under way, none of them phase 3. Stroke · The University of Texas Health Science Center, Houston.
Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, this one is the 23rd largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 33rd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →6 of the 39 studies in Stroke by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 55+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 22–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 13–21
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 4 4
First in 2001; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 21 across the 35 interventional studies, 339 across the 4 observational. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
1 of the studies in Stroke by The University of Texas Health Science Center, Houston that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06280482The University of Texas Health Science Center, HoustonNicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) | 2027-07-25 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nicotinamide riboside (NR)
Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
Change in systolic blood
Time frame: Baseline , 8 weeks
Change in cerebral oxygenation and perfusion as assessed by the Head-up tilt table testing (HUTT) with near-infrared spectroscopy (NIRS) monitoring.
Time frame: Baseline , 8 weeks
Change in cognitive function as assessed by the NIH Toolbox assessment
NIH Toolbox assessment evaluates multiple domains of cognitive performance including executive function, attention, episodic memory, language, processing speed, and working memory. Individual test scores are combined into a composite cognition score and reported as age-adjusted T-scores (mean = 50, SD = 10), where higher scores indicate better cognitive function.
Time frame: Baseline , 8 weeks
Change in autonomic symptoms as assessed by the Composite Autonomic Symptom Score 31 (COMPASS-31) survey
This is a 31 item questionnaire and each is scored from 0 (no symptoms) to 100(maximum symptom burden), with higher scores indicating more severe autonomic dysfunction.
Time frame: Baseline , 8 weeks
Change in Impact of headaches as assessed by the Headache Impact Test (HIT-6) questionnaire
HIT-6 questionnaire consists of 6 questions, each scored from 6(never) to 13(always), with total scores ranging from 36 to 78. Higher scores indicate a greater impact of headaches on quality of life.
Time frame: Baseline, 8 weeks
Pulmonary function tests (PFTs), including spirometry and lung volume measurements
Time frame: Baseline, 8 weeks
Change in Aortic diameter as assessed by the echocardiography
Time frame: Baseline , 8 weeks
Change in Levels of Nicotinamide adenine dinucleotide (NAD+) in whole blood as measured by high-performance liquid chromatography (HPLC)
Time frame: Baseline , 8 weeks
Change in Levels of NR in whole blood as measured by high-performance liquid chromatography (HPLC)
Time frame: Baseline , 8 weeks
Safety as assessed by number of participants that show drug toxicity as shown in bloodwork
Time frame: Baseline
Safety as assessed by number of participants that show drug toxicity as shown in bloodwork
Time frame: end of study (8 weeks after baseline)
Tolerability as assessed by the number of patients who complete study
Time frame: end of study( 8 weeks after baseline)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.
Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 40 months is above that.
Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicotinamide-beta-riboside
The University of Texas Health Science Center, Houston →